

## Evaluation Report for Category B, Subcategory 3.11 Application

**Application Number:** 2024-0158  
**Application:** New or Changes to Product Labels: New Pests  
**Product:** Lumivia CPL Insecticide Seed Treatment  
**Registration Number:** 33335  
**Active ingredient (a.i.):** Chlorantraniliprole  
**PMRA Document Number:** 3589169

### Background

Lumivia CPL Insecticide Seed Treatment (Reg. No. 33335) is a flowable suspension seed treatment product formulated with 625 g/L chlorantraniliprole, registered for the early season protection of cereal and dry legume vegetables from wireworms, cutworms, armyworm (*Mythimna unipuncta*) and pea leaf weevil larvae. Lumivia CPL Insecticide Seed Treatment is applied at rates of 8 – 96 mL product (5 – 60 g a.i.)/100 kg seed, dependent upon the target pest and crop. For full details of the registered use pattern, refer to the product label.

### Purpose of Application

The purpose of this application is to add the suppression of grasshoppers on wheat, barley, oats and rye to the label of Lumivia CPL Insecticide Seed Treatment.

### Chemistry, Health, and Environmental Assessments

Chemistry, health, and environmental assessments were not required as there was no change to the product formulation and as there was no change to the use pattern, including application rates, methods and timings.

### Value Assessment

Based on the results from the efficacy trials and a use history rationale from this existing use on the US registered product, Lumivia CPL Insecticide Seed Treatment suppresses grasshoppers on wheat, barley, oats and rye. The value information provided was sufficient to support the suppression of grasshoppers at an application rate of 40 mL product (25 g chlorantraniliprole)/100 kg seed.

### Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided and has found the information acceptable to add the suppression of grasshoppers on wheat, barley, oats and rye to the label of Lumivia CPL Insecticide Seed Treatment.

## References

- 3544514 2024, Value Summary, DACO 10.1
- 3544515 2024, 10.2.3.1, 10.2.3.3D Raw Data Master Summary Table, DACO: 10.2.3.3(D)
- 3544516 2024, Efficacy Trial Reports, DACO: 10.2.3.3(D), 10.3.1, 10.3.2

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.